About the Company
We do not have any company description for Compass Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Compass Therapeutics, Inc.
Compass Therapeutics (CMPX) Rated ‘Outperform’ amid Clinical Pipeline Development
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top multibagger penny stocks to buy, according to analysts. On August ...
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does ... - Nasdaq
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress
Compass Therapeutics, Inc. ( ($CMPX) ) has released its Q2 earnings. Here is a breakdown of the information Compass Therapeutics, Inc. presented ...
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation ...
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The ...
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
To Obtain Global Rights to TR009, A Novel bispecific antibody and Inhibitor of the Notch Pathway Targeting DLL4 and VEGF-A. BOSTON& IRVINE, Calif.---- Compass Therapeutics, Inc., a clinical-stage ...
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
Compass Therapeutics, Inc. (NASDAQ:CMPX) is up 101.38% year-to-date. Overall CMPX ranks 2nd on our list of the biotech stocks that are skyrocketing so far in 2025.
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers ...
Compass Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for CMPX's full-year earnings has moved 15.4% higher within the past quarter.
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th ...
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics ...
Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far ...
We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at where Compass Therapeutics, Inc.
Compass Therapeutics, Inc. Provides Corporate Update
Contacts Compass Therapeutics, Inc. Samuel Perry, Sr. Director, Operations media@compasstherapeutics.com 617-500-8099 ...
Similar Companies
Loading the latest forecasts...